Compare Stocks: NUVL, ONC, TEVA, and ROIV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NUVL Nuvalent	$123.96	$118.13	$71.13 ▼ $123.99	$9.79B	1.14	1.93 million shs	N/A
ONC BeOne Medicines	$316.01 -1.9%	$293.50	$253.95 ▼ $385.22	$35.34B	0.49	362,442 shs	249,956 shs
ROIV Roivant Sciences	$33.91 -1.8%	$32.63	$10.90 ▼ $37.00	$24.83B	1.11	4.38 million shs	5.40 million shs
TEVA Teva Pharmaceutical Industries	$35.05 -1.0%	$33.24	$14.99 ▼ $37.35	$40.71B	0.86	5.41 million shs	4.69 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NUVL Nuvalent	0.00%	0.00%	+0.29%	+25.16%	+55.85%
ONC BeOne Medicines	-1.88%	-3.03%	+8.69%	+7.54%	+5.36%
ROIV Roivant Sciences	-1.77%	-3.14%	-3.20%	+21.85%	+197.46%
TEVA Teva Pharmaceutical Industries	-1.14%	+13.85%	+4.60%	+0.14%	+108.24%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NUVL Nuvalent	$123.96	$118.13	$71.13 ▼ $123.99	$9.79B	1.14	1.93 million shs	N/A
ONC BeOne Medicines	$316.01 -1.9%	$293.50	$253.95 ▼ $385.22	$35.34B	0.49	362,442 shs	249,956 shs
ROIV Roivant Sciences	$33.91 -1.8%	$32.63	$10.90 ▼ $37.00	$24.83B	1.11	4.38 million shs	5.40 million shs
TEVA Teva Pharmaceutical Industries	$35.05 -1.0%	$33.24	$14.99 ▼ $37.35	$40.71B	0.86	5.41 million shs	4.69 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NUVL Nuvalent	0.00%	0.00%	+0.29%	+25.16%	+55.85%
ONC BeOne Medicines	-1.88%	-3.03%	+8.69%	+7.54%	+5.36%
ROIV Roivant Sciences	-1.77%	-3.14%	-3.20%	+21.85%	+197.46%
TEVA Teva Pharmaceutical Industries	-1.14%	+13.85%	+4.60%	+0.14%	+108.24%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NUVL Nuvalent	2.15	Hold	$127.73	3.04% Upside
ONC BeOne Medicines	2.88	Moderate Buy	$394.00	24.68% Upside
ROIV Roivant Sciences	2.75	Moderate Buy	$33.59	-0.94% Downside
TEVA Teva Pharmaceutical Industries	2.80	Moderate Buy	$42.00	19.84% Upside

Current Analyst Ratings Breakdown

Latest NUVL, ONC, TEVA, and ROIV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	ROIV Roivant Sciences	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/28/2026	TEVA Teva Pharmaceutical Industries	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$42.00 ➝ $44.00
7/27/2026	ONC BeOne Medicines	Nomura Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/23/2026	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$415.00 ➝ $425.00
7/17/2026	ONC BeOne Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	TEVA Teva Pharmaceutical Industries	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	ONC BeOne Medicines	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$409.00 ➝ $403.00
7/7/2026	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$436.00 ➝ $451.00
7/7/2026	ONC BeOne Medicines	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$413.00 ➝ $416.00
7/3/2026	ONC BeOne Medicines	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/1/2026	ONC BeOne Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$396.00

(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NUVL Nuvalent	N/A	N/A	N/A	N/A	$15.95 per share	N/A
ONC BeOne Medicines	$5.34B	6.49	$3.84 per share	82.40	$39.77 per share	7.95
ROIV Roivant Sciences	$8.26M	2,952.84	N/A	N/A	$7.35 per share	4.61
TEVA Teva Pharmaceutical Industries	$17.26B	2.33	$3.69 per share	9.49	$6.75 per share	5.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NUVL Nuvalent	-$425.38M	-$6.06	N/A	N/A	N/A	N/A	-40.11%	-35.43%	8/6/2026 (Estimated)
ONC BeOne Medicines	$286.93M	$4.47	70.70	29.78	N/A	8.94%	12.06%	6.69%	8/5/2026 (Confirmed)
ROIV Roivant Sciences	-$299.77M	-$0.60	N/A	N/A	N/A	-3,629.19%	-20.54%	-19.43%	8/6/2026 (Estimated)
TEVA Teva Pharmaceutical Industries	$1.41B	$1.33	58.41	11.53	3.74	4.08%	32.64%	6.34%	N/A

Latest NUVL, ONC, TEVA, and ROIV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	NUVL Nuvalent	-$1.44	N/A	N/A	N/A	$0.25 million	N/A
8/6/2026	Q1 2027	ROIV Roivant Sciences	-$0.2881	N/A	N/A	N/A	$2.00 million	N/A
7/29/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	$0.08	$0.02	-$0.06	-$0.49	$4.02 billion	$4.14 billion
6/30/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	N/A	$0.02	N/A	-$0.49	N/A	$4.14 billion
5/7/2026	Q1 2026	NUVL Nuvalent	-$1.35	-$1.39	-$0.04	-$1.39	$0.49 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NUVL Nuvalent	N/A	16.14	16.14
ONC BeOne Medicines	0.20	3.64	3.27
ROIV Roivant Sciences	N/A	18.37	18.37
TEVA Teva Pharmaceutical Industries	1.56	0.88	0.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NUVL Nuvalent	97.26%
ONC BeOne Medicines	48.55%
ROIV Roivant Sciences	64.76%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
NUVL Nuvalent	5.02%
ONC BeOne Medicines	6.19%
ROIV Roivant Sciences	10.80%
TEVA Teva Pharmaceutical Industries	0.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NUVL Nuvalent	40	79.00 million	75.03 million	Optionable
ONC BeOne Medicines	12,000	109.72 million	102.93 million	N/A
ROIV Roivant Sciences	860	719.27 million	641.59 million	Optionable
TEVA Teva Pharmaceutical Industries	33,950	1.15 billion	1.14 billion	Optionable

NUVL, ONC, TEVA, and ROIV Headlines

Recent News About These Companies

Janus Henderson Group PLC Has $145.08 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

August 1 at 6:07 AM | marketbeat.com

Axiom Investment Management LLC Takes $965,000 Position in Teva Pharmaceutical Industries Ltd. $TEVA

August 1 at 3:40 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. $TEVA Stake Boosted by Avidity Partners Management LP

August 1 at 3:27 AM | marketbeat.com

Teva Shares Climb as Revenue Beat and Innovative Drug Growth Offset Earnings Miss

July 31 at 7:59 PM | investorshub.advfn.com

Teva Pharmaceutical Industries Limited 2026 Q2 - Results - Earnings Call Presentation

July 31 at 7:09 PM | seekingalpha.com

RBF Capital LLC Sells 30,000 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

July 31 at 5:44 AM | marketbeat.com

Dimensional Fund Advisors LP Purchases 73,410 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

July 31 at 3:44 AM | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Up 8.2% Following Analyst Upgrade

July 31 at 1:41 AM | americanbankingnews.com

Investors Purchase High Volume of Put Options on Teva Pharmaceutical Industries (NYSE:TEVA)

July 30 at 5:19 PM | marketbeat.com

Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight

July 30 at 1:40 PM | finance.yahoo.com

Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises

July 30 at 1:40 PM | finance.yahoo.com

Teva (TEVA) Lifts UZEDY Outlook After Record Sales And New FDA Progress

July 30 at 1:40 PM | finance.yahoo.com

Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises

July 30 at 1:26 PM | zacks.com

Is Teva (TEVA) Trading Profit for Future Potential With Its Branded‑Drug Pivot?

July 30 at 8:39 AM | finance.yahoo.com

Is Teva Pharmaceutical Industries (TEVA) A Bargain After Results And Higher Revenue Guidance?

July 30 at 8:39 AM | finance.yahoo.com

Teva Pharmaceutical Industries Q2 Earnings Call Highlights

July 30 at 8:02 AM | marketbeat.com

Tri Locum Partners LP Has $30.75 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

July 30 at 6:31 AM | marketbeat.com

181,294 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by Healthcare of Ontario Pension Plan Trust Fund

July 30 at 5:11 AM | marketbeat.com

Principal Financial Group Inc. Decreases Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

July 30 at 4:31 AM | marketbeat.com

Teva Pharmaceutical Industries Target of Unusually Large Options Trading (NYSE:TEVA)

July 30 at 3:41 AM | americanbankingnews.com

Piper Sandler Forecasts Strong Price Appreciation for Teva Pharmaceutical Industries (NYSE:TEVA) Stock

July 30 at 3:03 AM | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NUVL, ONC, TEVA, and ROIV Company Descriptions

Nuvalent NASDAQ:NUVL

$123.96 0.00 (0.00%)

As of 07/16/2026

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

BeOne Medicines NASDAQ:ONC

$316.01 -6.07 (-1.88%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$315.05 -0.96 (-0.30%)

As of 07/31/2026 07:34 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Roivant Sciences NASDAQ:ROIV

$33.91 -0.61 (-1.77%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$34.40 +0.49 (+1.46%)

As of 07/31/2026 07:53 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Teva Pharmaceutical Industries NYSE:TEVA

$35.05 -0.36 (-1.03%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$34.54 -0.51 (-1.45%)

As of 07/31/2026 07:55 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NUVL, ONC, TEVA, and ROIV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NUVL, ONC, TEVA, and ROIV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NUVL, ONC, TEVA, and ROIV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NUVL, ONC, TEVA, and ROIV Company Descriptions

Nuvalent NASDAQ:NUVL

BeOne Medicines NASDAQ:ONC

Roivant Sciences NASDAQ:ROIV

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NUVL, ONC, TEVA, and ROIV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NUVL, ONC, TEVA, and ROIV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NUVL, ONC, TEVA, and ROIV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NUVL, ONC, TEVA, and ROIV Company Descriptions

Nuvalent NASDAQ:NUVL

BeOne Medicines NASDAQ:ONC

Roivant Sciences NASDAQ:ROIV

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools